Key Takeaways
- Volume-led growth in a soft pricing cycle: Sales volumes rose 10% YoY while aroma chemical prices sit below 2018 levels, compressing margins. Management is running the plants for volume and market share, betting prices have bottomed.
- Mahad greenfield is the near-term margin drag: The new site is running at 30–35% utilization and consuming profitability; the ramp-up clock only started in June 2025 and commercial sampling began in August/September.
- Tariff overhang is lifting: Management declared the US tariff situation "has gone" and India's duty advantage over China restored; the EU trade deal adds a second tailwind. American buyers had been buying hand-to-mouth, suppressing an estimated 6–9% of 9M sales.
- Fragrance division is the bright spot: Strong performance driven by softer raw material pricing and new customer wins, with the perfumery R&D pipeline feeding the ingredients business.
- What to watch next quarter: Whether Mahad utilization ticks materially above 35%, whether the restored tariff clarity actually converts to US order flow, and whether aroma chemical prices begin to lift off what management calls the bottom.
Volume Strategy vs Pricing Reality
- Sales maximization mode: The company is deliberately prioritizing volumes and market share over price in a buyer's market, with 9M production up 11% YoY and sales volumes up 10% YoY. Management is not overselling where pricing is incorrect.
- Aroma chemical prices at multi-year lows: Prices are even lower than 2018 levels; management believes they have "bottomed out" as far as chemical prices are concerned.
- Camphor profitability under pressure: The camphor product line is under profitability pressure, which drags on the FMCG segment's normal outcome, even though the FMCG segment itself "continues to stay stronger."
- Pricing power triggers: Better realizations depend on petro-based or natural raw material prices rising, or a general shift in starting raw materials. Meanwhile, the company is improving internal processes.
- Chinese camphor dynamics: Natural camphor imports from China were lower in 9M FY26 versus the prior three years, and Chinese natural camphor prices have started increasing and aligning with Indian camphor.
- Structural evolution since 2018: The company now has a larger range of materials feeding its fragrance division and has internalized formulated camphor, positioning it differently than in the last downcycle.
Management: "Between 2018 and 2026, we see a completely different oriental where we have a large range of materials. These materials are used by our fragrance division. We have internalized our formulated camphor. So, a lot of things are now ready for action when the opportunities come."
Mahad Greenfield: The Ramp-Up Equation
- The drag: Mahad is in stabilization phase and is a near-term drag on consolidated profitability; the drag is expected to reduce progressively as utilization rises.
- The timeline: Real production only started in June 2025; the plant is running at 30–35% of capacity after seven months. First commercial sampling for global customers began in August/September 2025, and there is a six-month cycle between sample submission and commercial approval.
- The investment burden: The site required land development for the whole site during phase one, which consumed a substantially large chunk of the investment, making the initial cost base heavier than a typical brownfield expansion.
- The comparison: Management noted that between 2018 and 2026, multiple large brownfield plants were commissioned and reached expected sales levels within 1,000 days; Mahad had a one-year aberration due to global geopolitical confusion.
- Profitability inflection: The next two quarters should see Mahad getting into "some level of independence," though no specific timeline was given for reaching 70–75% utilization.
Management: "we already have reached around, I mean, to be very honest, the real production in that plant has only started from June 2025. So, in seven months, we are already seeing that the plant is running at anywhere between 30% to 35% of its capacity."
Trade & Tariff: The Demand Reset
- US tariff overhang resolved: Management stated the US tariff situation "has gone" and should be put to rest; India's tariff advantage over China has been restored. There is a 14% duty differential between Chinese companies and Oriental Aromatics, giving some hope for pricing power.
- The 9M impact: 16–20% of sales are oriented to America. Due to tariff uncertainty, American customers were buying hand-to-mouth; management estimates 6% to 9% more sales would have been expected in 9M FY26 had tariffs not been there or there was clarity on landed cost. Management declined to quantify the exact financial impact.
- EU trade deal tailwind: The EU trade deal is positive news expected to help increase sales.
- Geopolitical ripple effects: US buyer caution caused global suppliers to focus on Europe; European buyers then slowed because they felt too much material was in the market, creating a compound demand drag.
Dharmil A. Bodani: "So, if you are asking us a forward-looking question on the impact of this trade deal that we have had with the United States, it is extremely positive. I think it is in the right direction."
Segment Performance
| Segment | Trend | Commentary |
|---|---|---|
| Fragrance | ▲ Strong | Very strong performance with sustainable benefits from softer raw material pricing and new wins with existing and new customers. R&D pipeline driven by the perfumery division acting as a beacon for the ingredients division. |
| Camphor | ▼ Under pressure | Profitability under pressure, impacting the FMCG segment's normal outcome. The company is the world's only US FDA approved camphor manufacturer and also holds WHO and GMP certifications, playing a large role globally in the medical pain management space. |
| Bareilly | ▲ Growth | Sales up 27% YoY despite being down sequentially, consistent with the seasonal curve. |
| Baroda | ▬ Resilient | Production up 15% YoY while the broader specialty ingredients market remains competitive and price sensitive. |
| FMCG | ▬ Steady | Continues to stay stronger, though camphor profitability pressure weighs on segment outcomes. Management declined to discuss FMCG sales strategy on the call. |
Balance Sheet & Asset Cycle
- Asset-creation phase complete: The past two to three years have been very asset-creation heavy; all assets are now on the ground and need to be filled up and sold to capacity.
- Net debt-to-equity at 0.65x: Keeps the company positioned to fund growth while managing volatility.
- EBITDA margin at 5.26%: Reflects pricing pressure in ingredients, the Mahad ramp-up drag, and a seasonally less favorable Q3 demand mix versus Q2.
- Seasonal pattern: Q3 is typically softer than Q2 because camphor is a strong seasonal product tied to the festive season, and similar seasonality affects the fragrance business.
Shyamal A. Bodani: "Importantly, when you step back and view performance the way global peers encourage investors to view it over a long arc rather than a quarter-to-quarter noise, the trend is reassuring."
Unanswered Questions & Pushback
- Camphor anti-dumping: An analyst asked about steps taken against anti-dumping duty on camphor imports and when action would happen. Management said "nothing has proceeded so far" and shifted to internal process optimization.
- Camphor without GST: An analyst asked about camphor being available in the market without GST and what steps the company has taken. Management did not answer this question.
- North America quantification: Management declined to give exact numbers on North America exposure and the quantified impact on nine-month financials from tariff uncertainty, offering only the 16–20% range and the 6–9% estimated sales impact.
- Mahad specifics: An analyst asked for total capacity at Mahad, ideal domestic/export split, timeline to reach 70–75% utilization, and broader capacity plans. Management did not provide specific numbers or timelines.
- FMCG strategy: Management declined to discuss FMCG sales strategy, new launches, or digital/e-commerce initiatives on the investor call.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Sales growth | 8% to 10% growth in sales | FY26 (current fiscal year) |
| Mahad profitability inflection | Getting into "some level of independence" | Next two quarters |
| Order book execution | "Pretty solid" order book; execute and continue same trajectory | H1 2026 |
| US tariff situation | Declared resolved; "no rearview mirror" | Effective immediately |
| Mahad utilization target | No specific timeline given for 70–75% utilization | Not provided |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Operating revenue | ₹252.03 cr, ~13% YoY growth |
| EBITDA | ₹13 cr, vs ₹23 cr in Q3 FY25 |
| EBITDA margin | 5.26% |
| Net loss | ₹1.92 cr, vs net profit of ₹7.14 cr in Q3 FY25 |
| PAT margin | (-0.76%) |
| Operating revenue (9M FY26) | ₹748 cr, 11% YoY increase |
| EBITDA (9M FY26) | ₹49 cr, vs ₹73 cr in 9M FY25 |
| EBITDA margin (9M FY26) | 6.49%, vs 10.85% in 9M FY25 |
| Net loss (9M FY26) | ₹0.67 cr, vs net profit of ₹32.90 cr in 9M FY25 |
| Cash profit (9M FY26) | ₹22.65 cr |
| Net debt-to-equity | 0.65x as of 31st Dec 2025 |
| Production growth | 3% YoY |
| Sales volume growth | 10% YoY |
| Mahad plant utilization | 30% to 35% of capacity, production started June 2025 |
| US sales exposure | 16% to 20% of total sales |